|
| |
Publications 1997
1997-1 BUEE-SCHERRER V, BUEE L, LEVEUGLE
B, PERL DP, VERMERSCH P, HOF PR, DELACOURTE A. Pathological Tau proteins
in postencephalitic parkinsonism: comparison to Alzheimer's disease
and other neurodegenerative disorders. Ann Neurol 1997, 42, 356-359.
1997-2 DAVID JP, GHOZALI F, FALLET-BIANCO C, WATTEZ A, DELAINE S, BONIFACE
B, DIMENZA C, DELACOURTE A. Glial reaction in the hippocampus formation
is highly correlated with aging. Neurosci. Lett. 235: 53-56.
1997-3 DELACOURTE A, BUÉE L. Normal and pathological Tau proteins
as factors for microtubule assembly. Int. Rev. Cytol, 1997, 171:167-224.
1997-5 Lambert Jc, Perez-Tur J, Dupire Mj, Galasko D, Mann D, Amouyel
P, Hardy J, Delacourte A, Chartier-Harlin Mc. Distortion of allelic
expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet
1997; 6: 2151-4.
1997-6 Sergeant N, David JP, Goedert M, Jakes R, Vermersch P, Buee L,
Lefranc D, Wattez A, Delacourte A. Two-dimensional Characterization
of PHF-Tau from Alzheimer's disease: Demonstration of an additional
74 kDa Component and Age-Related Biochemical Modifications. J Neurochem.
1997, 69: 834-844.
1997-7 SERGEANT, N. DAVID, JP. LEFRANC, D. VERMERSCH, P. WATTEZ, A.
DELACOURTE A. (1997) Different distribution of phosphorylated Tau protein
isoforms in Alzheimer's and Pick's diseases. FEBS Lett. 412:578-582.
1997-9 WAVRANT-DEVRIEZE F, PEREZ-TUR J, LAMBERT JC, FRIGARD B, PASQUIER
F, DELACOURTE A, AMOUYEL P, HARDY J, CHARTIER-HARLIN MC. Association
between the low density lipoprotein receptor-related protein (LRP) and
Alzheimer’ disease. Neurosci Lett 1997. 227:68-70
-
Ann N Y Acad Sci 1997 Sep 26;826:7-24
Brain microvascular changes in Alzheimer's disease and other dementias.
Buee L, Hof PR, Delacourte A
Vasculopathy in Alzheimer's disease (AD) may represent an important
pathogenetic factor of this disorder. In the present study, microvasculature
was studied by immunohistochemistry using a monoclonal antibody against
a vascular heparan sulfate proteoglycan. Vascular changes were consistently
observed in AD and included decrease in vascular density, presence of
atrophic and coiling vessels, and glomerular loop formations. The laminar
and regional distribution of these vascular alterations was correlated
with the presence of neurofibrillary tangles. However, vascular changes
may also follow neuronal loss. Vascular density may be related to a
decrease in brain metabolism. Furthermore, one of the main features
of AD is the presence of amyloid deposits within brain parenchyma and
blood vessel walls. It is not yet clear whether amyloid components are
derived from the blood or the central nervous system. Because AD is
clearly heterogeneous, based on clinical and genetic data, evidence
for either a brain or peripheral origin is discussed. Microvasculature
was also analyzed in other neurodegenerative disorders devoid of amyloid
deposits including amyotrophic lateral sclerosis/parkinsonism-dementia
complex of Guam and Pick's disease. In conclusion, if vasculopathy in
neurodegenerative disorders is not directly involved in pathogenesis,
it may act synergistically with other pathogenetic mechanisms including
genetic and environmental factors. This aspect of pathology is particularly
interesting in view of its accessibility to therapeutic interventions.
PMID: 9329677, UI: 97470260
Ann Neurol 1997 Sep;42(3):356-359
Pathological tau proteins in postencephalitic parkinsonism: comparison
with Alzheimer's disease and other neurodegenerative disorders.
Buee-Scherrer V, Buee L, Leveugle B, Perl DP, Vermersch P, Hof PR,
Delacourte A
Immunohistochemical and biochemical analyses of hyperphosphorylated
tau proteins, the major component of neurofibrillary tangles, were performed
in different brain regions from patients presenting with postencephalitic
parkinsonism. Neurofibrillary tangles were found in hippocampus, neocortical
areas (mostly in supragranular layers), and several subcortical structures.
By immunoblotting, a tau protein triplet similar to the one seen in
Alzheimer's disease was observed. This biochemical approach allows for
the definition of postencephalitic parkinsonism from certain neurodegenerative
disorders such as progressive supranuclear palsy and corticobasal degeneration.
PMID: 9307257, UI: 97450816
Neurosci Lett 1997 Oct 10;235(1-2):53-56
Glial reaction in the hippocampal formation is highly correlated with
aging in human brain.
David JP, Ghozali F, Fallet-Bianco C, Wattez A, Delaine S, Boniface
B, Di Menza C, Delacourte A
Service de Gerontologie Clinique, Hopital Emile Roux, Limeil Brevannes,
France.
Glial fibrillary acidic protein (GFAP), a biochemical marker of astrocytes
and glial reaction, was quantified by immunoblotting in different brain
areas from 33 non-demented patients with a Mini Mental State Examination
score above 26 and aged from 12 to 98 years. An increase of GFAP with
age was first found in the hippocampus and then in the entorhinal cortex.
In both regions, GFAP amounts were correlated with age (r = 0.768).
In the isocortex, the increase of GFAP as a function of age was also
significant (r = 0.672), but less than for the hippocampal region. GFAP
levels increased dramatically after the age of 65 years, and more especially
in the hippocampal formation. This glial reaction was observed in aged
controls that do not show cognitive impairment and the neuropathological
hallmarks of Alzheimer's disease.
PMID: 9389594, UI: 98049462
- DELACOURTE A, SERGEANT N, ROBITAILLE Y, BUEE-SCHERRER V, BUEE L,
DAVID JP, BUSSIERE T, VERMERSCH P, HOF PR, GAUVREAU D, WATTEZ A.
Pathological Tau proteins are biochemical markers that differentiate
several types of neurofibrillary degeneration.
- in Alzheimer s disease: Biology, diagnosis and Therapeutics.
Edited by K. Iqbal, B. Winblad, T. Nishimura, M. Takeda and H.
Wisniewski. 1997
Int Rev Cytol 1997;171:167-224
Normal and pathological Tau proteins as factors for microtubule assembly.
Delacourte A, Buee L
Tau proteins are microtubule-associated proteins. They regulate the
dynamics of the microtubule network, especially involved in the axonal
transport and neuronal plasticity. Tau proteins belong to a family of
developmentally regulated isoforms generated by alternative splicing
and phosphorylation. This generates several Tau variants that interact
with tubulin and other proteins. Therefore, Tau proteins are influenced
by many physiological regulations. Tau proteins are also powerful markers
of the neuronal physiological state. Their degree of phosphorylation
is a good marker of cell integrity. It is heavily disturbed in numerous
neurodegenerative disorders, leading to a collapse of the microtubule
network and the presence of intraneuronal lesions resulting from Tau
aggregation. However, different biochemical and immunological patterns
of pathological Tau proteins found among neurodegenerative disorders
are useful markers for the understanding of the role of Tau protein
isoforms and the diagnosis of these pathological conditions.
Publication Types:
PMID: 9066128, UI: 97218704
Neurobiol Dis 1997;4(5):356-364
ApoE synthesis in human neuroblastoma cells.
Dupont-Wallois L, Soulie C, Sergeant N, Wavrant-de Wrieze N, Chartier-Harlin
MC, Delacourte A, Caillet-Boudin ML
INSERM U422, Lille, France.
Apolipoprotein E (apoE) is associated with the two hallmarks of Alzheimer's
disease: A beta deposits and neurofibrillary tangles. ApoE synthesis
was detected in astrocytes by in situ hybridization but was not detected
in neurons. Nevertheless, different studies on apoE immunoreactivity
reported the presence of apoE in neurons of Alzheimer, control, and
necrosis pontisubicular brains. In this study, we addressed the question
of potential synthesis of apoE in neurons and its possible involvement
in or in response to pathological conditions. To this purpose, we have
studied human neuronal cell lines (SY 5Y and Kelly cells) originating
from neuroblastoma. Using monoclonal and polyclonal antibodies, a 32-kDa
band was detected in SY 5Y and Kelly cells, before and after NGF differentiation.
Two-dimensional gel electrophoresis analysis showed a typical profile
of apoE spots resolved to the exact isoelectric points. By reverse transcription-polymerase
chain reaction experiments, we demonstrated the presence of apoE mRNA
in these cell lines. SY 5Y cells synthesized the apoE3 variant, whereas
Kelly cells expressed both apoE3 and apoE4 isoforms, corroborating the
two-dimensional gel results. These results suggested that apoE synthesis
could occur in human neuronal cell lines under certain conditions.
- PMID: 9440124, UI: 98103298
-
Hum Mol Genet 1997 Nov;6(12):2151-2154
Distortion of allelic expression of apolipoprotein E in Alzheimer's
disease.
Lambert JC, Perez-Tur J, Dupire MJ, Galasko D, Mann D, Amouyel P,
Hardy J, Delacourte A, Chartier-Harlin MC
The APOE straightepsilon4 allele is a strong genetic susceptibility
factor for Alzheimer's disease. Interaction with other biological factors
may modulate the effect of the apoE isoforms. However, previous work
suggested that other genetic variability within the APOE locus, influencing
the effect of the straightepsilon4 allele, may exist. Such variability
could modify the expression of the APOE gene and, in particular, the
level of expression of APOE alleles could be an important determinant
of disease pathogenesis. To test this hypothesis we examined the levels
of expression of APOE in heterozygotes with AD and in controls, using
a new method of semi-quantitation. We report that relative straightepsilon4
mRNA expression is increased in AD compared with controls and suggest
that genetic variability in the neural expression of APOE contributes
to disease risk.
- PMID: 9328480, UI: 97472468
-
-
FEBS Lett 1997 Aug 4;412(3):578-582
Different distribution of phosphorylated tau protein isoforms in Alzheimer's
and Pick's diseases.
Sergeant N, David JP, Lefranc D, Vermersch P, Wattez A, Delacourte
A
Tau proteins aggregate into different neuronal inclusions in several
neurodegenerative disorders. In Alzheimer's disease (AD), hyperphosphorylated
Tau from paired helical filaments (PHF) of neurofibrillary tangles,
named PHF-Tau, have an electrophoretic profile with four main bands
(Tau 55, 64, 69, 74 kDa). In Pick's disease, phosphorylated Tau from
Pick bodies are made of two major components (Tau 55, 64 kDa) and a
minor 69 kDa. Here we show, using specific antibodies against translated
exon 2, 3 or 10 of Tau isoforms, that the set of Tau isoforms engaged
in the most insoluble part of PHF in AD is made of Tau isoforms with
exon 10 while they are lacking in phosphorylated Tau from Pick's disease.
Our results suggest that specific sets of Tau isoforms distinguish between
typical neuronal inclusions.
- PMID: 9276470, UI: 97420485
J Neurochem 1997 Aug;69(2):834-844
Two-dimensional characterization of paired helical filament-tau from
Alzheimer's disease: demonstration of an additional 74-kDa component
and age-related biochemical modifications.
Sergeant N, David JP, Goedert M, Jakes R, Vermersch P, Buee L, Lefranc
D, Wattez A, Delacourte A
PHF-tau proteins are the major components of the paired helical filament
(PHF) from Alzheimer's disease (AD) neurofibrillary lesions. They differ
both qualitatively and quantitatively in their degree of phosphorylation
when compared with native tau proteins. However, little is known about
the extent and heterogeneity of phosphorylated sites or the isoform
composition and the isoelectric variants of PHF-tau. Therefore, we have
characterized PHF-tau proteins from cortical brain tissue homogenates
of 13 AD patients using two-dimensional gel electrophoresis. Whatever
the topographical origin of brain tissue homogenates, PHF-tau proteins
shared the same two-dimensional gel electrophoresis profile made of
a tau triplet of 55, 64, and 69 kDa. A 74-kDa hyperphosphorylated tau
component was detected particularly in the youngest and most severely
affected AD patients. This additional component of hyperphosphorylated
tau was shown to correspond to the longest brain tau isoform. Furthermore,
the isoelectric points of PHF-tau from older AD patients were significantly
more basic, indicating a lower degree of phosphorylation. These results
show that the severity of neurofibrillary degeneration of AD is modulated
by age.
- PMID: 9231745, UI: 97375428
- .
J Neurol Neurosurg Psychiatry 1997 Aug;63(2):240-246
Neurofibrillary tangles in Gerstmann-Straussler-Scheinker syndrome
with the A117V prion gene mutation.
Tranchant C, Sergeant N, Wattez A, Mohr M, Warter JM, Delacourte A
One patient of a French family with Gerstmann-Straussler-Scheinker
syndrome with the mutation in codon 117 of the prion protein (PrP) gene
displayed unexpected neuritic degeneration around PrP plaques and numerous
diffuse neurofibrillary tangles, whereas other members did not. The
tau profile in this patient's brain was analysed and compared with one
from another member of the Gerstmann-Straussler-Scheinker family as
well as with the Alzheimer's tau profile. A panel of well characterised
antibodies against both normal tau protein and paired helical filaments-tau
protein was used on immunoblots of brain proteins resolved by mono and
two dimensional gels. The tau profile in the patient with Gerstmann-Straussler-Scheinker
syndrome without neurofibrillary tangles was normal. The tau profile
from the patient with Gerstmann-Straussler-Scheinker syndrome and neurofibrillary
tangles was characterised by a hyperaggregation state of tau protein.
This case illustrates the phenotypic heterogeneity of the GSS117 mutation
not only from one family to another, but also between members of the
same family. In this family, the presence of neurofibrillary tangles
is still unexplained, but could be correlated with either the protracted
duration of the disease or the old age of the patient.
- PMID: 9285466, UI: 97429828
Neurosci Lett 1997 May 9;227(1):68-70
Association between the low density lipoprotein receptor-related protein
(LRP) and Alzheimer's disease.
Wavrant-DeVrieze F, Perez-Tur J, Lambert JC, Frigard B, Pasquier F,
Delacourte A, Amouyel P, Hardy J, Chartier-Harlin MC
Alzheimer's disease (AD) is the most common neurodegenerative disorder
affecting elderly people. It usually occurs after 65 years old (late-onset
AD). The epsilon4 allele of apolipoprotein E (APOE) gene is a risk factor
which contributes about 50% of the genetic risk for this form of the
disease. The low density lipoprotein receptor-related protein (LRP)
is a major receptor for APOE which is found in the senile plaques of
AD brains. This makes it a good candidate gene for the disease. There
is a polymorphism in the region upstream of the LRP gene that has been
associated with AD in an American population. We examined this polymorphism
by restriction fragment length polymorphism analysis in a French population
with sporadic late-onset AD. In the previous report, a significant increase
of the 87 bp allele was found in the AD cases; however, in our population,
we observed a significant decrease with this same allele of the LRP
gene. The possible reasons for this discrepancy, linkage disequilibrium
or statistical anomaly, are discussed.
- PMID: 9178861, UI: 97322207
|